{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:25:48Z","timestamp":1782840348749,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI109039"],"award-info":[{"award-number":["R01AI109039"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D14FE-012"],"award-info":[{"award-number":["D14FE-012"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D16FE-512"],"award-info":[{"award-number":["D16FE-512"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.antiviral.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T07:41:05Z","timestamp":1518680465000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Fexaramine as an entry blocker for feline caliciviruses"],"prefix":"10.1016","volume":"152","author":[{"given":"Yunjeong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Ok","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2018.02.009_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2018.02.009_bib2","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1128\/JVI.00550-08","article-title":"Structural insights into calicivirus attachment and uncoating","volume":"82","author":"Bhella","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib3","doi-asserted-by":"crossref","first-page":"11381","DOI":"10.1128\/JVI.05621-11","article-title":"The cryo-electron microscopy structure of feline calicivirus bound to junctional adhesion molecule A at 9-angstrom resolution reveals receptor-induced flexibility and two distinct conformational changes in the capsid protein VP1","volume":"85","author":"Bhella","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.41.6.1220","article-title":"SCH 48973: a potent, broad-spectrum, antienterovirus compound","volume":"41","author":"Buontempo","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.02.009_bib5","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1128\/JVI.00301-08","article-title":"Leader of the capsid protein in feline calicivirus promotes replication of Norwalk virus in cell culture","volume":"82","author":"Chang","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib6","series-title":"Virus Taxonomy Classification and Nomenclature of Viruses Ninth Report of the International Committee on Taxonomy of Viruses","article-title":"Family Caliciviridae","author":"Clarke","year":"2012"},{"key":"10.1016\/j.antiviral.2018.02.009_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/med.20125","article-title":"Selective inhibitors of picornavirus replication","volume":"28","author":"De Palma","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.antiviral.2018.02.009_bib8","series-title":"The PyMOL Molecular Graphics System","author":"DeLano","year":"2010"},{"key":"10.1016\/j.antiviral.2018.02.009_bib9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.antiviral.2018.02.009_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.02.009_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jfms.2005.08.002","article-title":"Virulent systemic feline calicivirus infection: local cytokine modulation and contribution of viral mutants","volume":"8","author":"Foley","year":"2006","journal-title":"J. Feline Med. Surg."},{"key":"10.1016\/j.antiviral.2018.02.009_bib12","series-title":"Caliciviruses: the Noroviruses","author":"Green","year":"2007"},{"key":"10.1016\/j.antiviral.2018.02.009_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.antiviral.2013.03.017","article-title":"Entry inhibitors and their use in the treatment of HIV-1 infection","volume":"98","author":"Haqqani","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.02.009_bib14","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/jac\/dkw101","article-title":"In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71","volume":"71","author":"Ho","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.02.009_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000456168","article-title":"Farnesoid X receptor in mice prevents severe liver immunopathology during lymphocytic choriomeningitis virus infection","volume":"41","author":"Honke","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.antiviral.2018.02.009_bib16","series-title":"Cell Entry by Non-enveloped Viruses","author":"Johnson","year":"2010"},{"key":"10.1016\/j.antiviral.2018.02.009_bib17","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1021\/acs.jmedchem.7b00175","article-title":"A novel series of highly potent small molecule inhibitors of rhinovirus replication","volume":"60","author":"Kim","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.02.009_bib18","doi-asserted-by":"crossref","first-page":"12570","DOI":"10.1128\/JVI.05839-11","article-title":"Inhibitory effects of bile acids and synthetic farnesoid X receptor agonists on rotavirus replication","volume":"85","author":"Kim","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib19","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1128\/JVI.01348-12","article-title":"Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses","volume":"86","author":"Kim","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib20","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1128\/JVI.03688-14","article-title":"Broad-spectrum inhibitors against 3C-Like proteases of feline coronaviruses and feline caliciviruses","volume":"89","author":"Kim","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2017.10.004","article-title":"New class of early-stage enterovirus inhibitors with a novel mechanism of action","volume":"147","author":"Ma","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.02.009_bib22","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1128\/JVI.80.9.4482-4490.2006","article-title":"Junctional adhesion molecule 1 is a functional receptor for feline calicivirus","volume":"80","author":"Makino","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib23","doi-asserted-by":"crossref","first-page":"13608","DOI":"10.1128\/JVI.01509-07","article-title":"Identification of regions and residues in feline junctional adhesion molecule required for feline calicivirus binding and infection","volume":"81","author":"Ossiboff","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib24","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1128\/JVI.02371-09","article-title":"Conformational changes in the capsid of a calicivirus upon interaction with its functional receptor","volume":"84","author":"Ossiboff","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib25","series-title":"Fields Virology","first-page":"1647","article-title":"Orthomyxoviridae: the viruses and their replication","author":"Palese","year":"2007"},{"key":"10.1016\/j.antiviral.2018.02.009_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cvsm.2008.03.002","article-title":"Molecular virology of feline calicivirus","volume":"38","author":"Pesavento","year":"2008","journal-title":"Vet. Clin. North Am. Small Anim. Pract."},{"key":"10.1016\/j.antiviral.2018.02.009_bib27","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.00976-10","article-title":"Combinatorial approaches to the prevention and treatment of HIV-1 infection","volume":"55","author":"Pirrone","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.02.009_bib28","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1128\/AAC.49.9.3755-3761.2005","article-title":"Design of a small-molecule entry inhibitor with activity against primary measles virus strains","volume":"49","author":"Plemper","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.02.009_bib29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1006\/jmbi.1994.1439","article-title":"Three-dimensional structure of calicivirus","volume":"240","author":"Prasad","year":"1994","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib30","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.bmcl.2013.09.070","article-title":"Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors","volume":"23","author":"Prior","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2018.02.009_bib31","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1096\/fj.201500134","article-title":"Reciprocal regulation of farnesoid X receptor alpha activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes","volume":"30","author":"Radreau","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.antiviral.2018.02.009_bib32","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2018.02.009_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/13543784.10.2.369","article-title":"Pleconaril: a novel antipicornaviral drug","volume":"10","author":"Romero","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2018.02.009_bib34","doi-asserted-by":"crossref","first-page":"11540","DOI":"10.1128\/JVI.01745-14","article-title":"Characterization of the mode of action of a potent dengue virus capsid inhibitor","volume":"88","author":"Scaturro","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/viro.1995.1354","article-title":"RNA transcripts derived from a cloned full-length copy of the feline calicivirus genome do not require VpG for infectivity","volume":"210","author":"Sosnovtsev","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.02.009_bib36","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/JVI.79.7.4012-4024.2005","article-title":"Feline calicivirus VP2 is essential for the production of infectious virions","volume":"79","author":"Sosnovtsev","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/viro.2000.0579","article-title":"Identification and genomic mapping of the ORF3 and VPg proteins in feline calicivirus virions","volume":"277","author":"Sosnovtsev","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.02.009_bib38","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1128\/JVI.72.4.3051-3059.1998","article-title":"Cleavage of the feline calicivirus capsid precursor is mediated by a virus-encoded proteinase","volume":"72","author":"Sosnovtsev","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.009_bib39","first-page":"181","article-title":"Comment on the paper: a three-dimensional model to analyze drug-drug interactions. Prichard, M.N. and Shipman, C., Jr. (1990)","volume":"14","author":"Suhnel","year":"1992","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2018.02.009_bib40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.virusres.2013.09.008","article-title":"Structural and inhibitor studies of norovirus 3C-like proteases","volume":"178","author":"Takahashi","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.02.009_bib41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.antiviral.2008.01.002","article-title":"R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond","volume":"78","author":"Thys","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.02.009_bib42","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1128\/AAC.03328-14","article-title":"The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication","volume":"58","author":"Tijsma","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.02.009_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/INF.0000000000000497","article-title":"First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis","volume":"34","author":"Torres-Torres","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2018.02.009_bib44","first-page":"5447","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T05:11:00Z","timestamp":1603861860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217306484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":44,"alternative-id":["S0166354217306484"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.02.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fexaramine as an entry blocker for feline caliciviruses","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}